|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences (J.C.E., D.C.D., D.S.M., N.A.P., R.R.A., W.J.J.), and Department of Biological Sciences, State University of New York at Buffalo, Buffalo, New York (D.C.D., C.E.K., R.R.A.)
A mechanism-based model was developed to describe the time course of arthritis progression in the rat. Arthritis was induced in male Lewis rats with type II porcine collagen into the base of the tail. Disease progression was monitored by paw swelling, bone mineral density (BMD), body weights, plasma corticosterone (CST) concentrations, and tumor necrosis factor (TNF)-
, interleukin (IL)-1β, IL-6, and glucocorticoid receptor (GR) mRNA expression in paw tissue. Bone mineral density was determined by PIXImus II dual energy X-ray densitometry. Plasma CST was assayed by high-performance liquid chromatography. Cytokine and GR mRNA were determined by quantitative real-time polymerase chain reaction. Disease progression models were constructed from transduction and indirect response models and applied using S-ADAPT software. A delay in the onset of increased paw TNF-
and IL-6 mRNA concentrations was successfully characterized by simple transduction. This rise was closely followed by an up-regulation of GR mRNA and CST concentrations. Paw swelling and body weight responses peaked approximately 21 days after induction, whereas bone mineral density changes were greatest at 23 days after induction. After peak response, the time course in IL-1β, IL-6 mRNA, and paw edema slowly declined toward a disease steady state. Model parameters indicate TNF-
and IL-1β mRNA most significantly induce paw edema, whereas IL-6 mRNA exerted the most influence on BMD. The model for bone mineral density captures rates of turnover of cancellous and cortical bone and the fraction of each in the different regions analyzed. This small systems model integrates and quantitates multiple factors contributing to arthritis in rats.
Address correspondence to: Dr. William J. Jusko, Department of Pharmaceutical Sciences, University at Buffalo, SUNY, 565 Hochstetter Hall, Buffalo, NY 14260. E-mail: wjjusko{at}buffalo.edu
This article has been cited by other articles:
![]() |
H. Wong, M. Belvin, S. Herter, K. P. Hoeflich, L. J. Murray, L. Wong, and E. F. Choo Pharmacodynamics of 2-{4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 360 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Earp, D. C. DuBois, D. S. Molano, N. A. Pyszczynski, R. R. Almon, and W. J. Jusko Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced Arthritis J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 546 - 554. [Abstract] [Full Text] [PDF] |
||||